On April 4, 2024 Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, reported that an abstract reporting preclinical results of its non-viral, cell penetrating gene monoclonal antibody (GMAB) platform technology has been selected for poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024, taking place April 5 – 10, 2024 in San Diego, CA (Press release, Gennao, APR 4, 2024, View Source [SID1234641780]). The poster presentation will showcase exploratory research conducted through Gennao’s ongoing collaboration with the laboratory of Peter M. Glazer, M.D., Ph.D., Chair of the Department of Therapeutic Radiology, Professor of Genetics and Robert E. Hunter Professor of Therapeutic Radiology at the Yale School of Medicine. Specifically, the presentation will demonstrate the potential application of the GMAB platform as an antibody-drug conjugate (ADC) for the treatment of solid tumors.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details of the poster presentation are as follows:
Abstract Number: 5801
Title: Targeted delivery of Exatecan to tumors via a novel cell-penetrating, anti-DNA antibody
Session Title: Cancer Treatment: New Technologies
Session Date and Time: Tuesday, April 9, 2024; 1:30 p.m. – 5:00 p.m. Pacific Daylight Time
Presenter: Zaira Ianniello, Ph.D., Yale School of Medicine
Location: Poster Section 22; Poster Number 10